Low dose oral combination chemoprophylaxis with oseltamivir and amantadine for influenza A virus infections in mice

Journal of Chemotherapy

Volumn 19, Issue 3, 2007, Pages 295-303

  Masihi, K Noel ^a   Schweiger, B ^a   Finsterbusch, T ^a   Hengel, H ^a,b  

^a ROBERT KOCH INSTITUTE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Amantadine; Chemoprophylaxis; Influenza virus; Oseltamivir; Pandemic

Indexed keywords

AMANTADINE; OSELTAMIVIR; PROTEIN M2; ZANAMIVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; GENE SEQUENCE; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; LOW DRUG DOSE; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL RATE; VIRUS CULTURE; VIRUS REPLICATION;

EID: 34447513687     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.3.295     Document Type: Article

References (33)

1. Stephenson I, Democratis J. Influenza: current threat from avian influenza. Br Med Bull 2006;75-76:63-80.
2. Madjid M, Lillibridge S, Mirhaji P, Casscells W. Influenza as a bioweapon. J R Soc Med 2003;96, 7:345.
3. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet 2000;355, 9206:827-35.
4. Bantia S, Arnold CS, Parker CD, Upshaw R, Chand P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006;69, 1:39-45.
5. Sidwell RW, Smee DF. Peramivir BCX-1812, RWJ-270201: potential new therapy for influenza. Expert Opin Investig Drugs 2002;11, 6:859-69.
6. Hengel H, Masihi KN. Combinatorial immunotherapies for infectious diseases. Int Immunopharmacol 2003;3, 8:1159 -67.
7. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. J Antimicrob Chemother 1986;18 Suppl B:177-83.
8. Wilson SZ, Knight V, Wyde PR, Drake S, Couch RB. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980;17, 4:642-8.
9. Madren L, Shipman C Jr, Hayden FG. In vitro inhibitory effects of combinations of anti-influenza agents. Antiviral Chem Chemother 1995;6:109-13.
10. Smee DF, Bailey KW, Morrison AC, Sidwell RW. Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy 2002;48, 2:88-93.
11. Ghezzi P, Ungheri D. Synergistic combination of nacetylcysteine and ribavirin to protect from lethal influenza viral infection in a mouse model. Int J Immunopathol Pharmacol 2004;17, 1:99-102.
12. Govorkova EA, Fang HB, Tan M, Webster RG. Neuraminidase Inhibitor-Rimantadine Combinations Exert Additive and Synergistic Anti-Influenza Virus Effects in MDCK Cells. Antimicrob Agents Chemother 2004;48,12:4855-63.
13. Masihi KN, Brehmer W, Lange W, Ribi E. Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection. Int J Immunopharmacol 1983;5:403-10.
14. Haller O, Arnheiter H, Gresser I, Lindenmann J. Genetically determined, interferon-dependent resistance to influenza virus in mice. J Exp Med 1979;149, 3:601-12.
15. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985;4, 11:3021-4.
16. Johansson BE, Grajower B, Kilbourne ED. Infection-permissive immunization with influenza virus neuraminidase prevents weight loss in infected mice. Vaccine 1993;11, 10:1037-9.
17. Hayden FG. Antiviral resistance in influenza viruses - implications for management and pandemic response. N Engl J Med 2006;354, 8:785-8.
18. Abed Y, Goyette N, Boivin G. Generation and characterization of recombinant influenza A H1N1 viruses harboring amantadine resistance mutations. Antimicrob Agents Chemother 2005;49, 2:556-9.
19. Kato N, Eggers HJ. Inhibition of uncoating of fowl plague virus by 1-adamantanamine hydrochloride. Virology 1969;37, 4:632-41.
20. Ciampor F, Bayley PM, Nermut MV, Hirst EM, Sugrue RJ, Hay AJ. Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment. Virology 1992;188, 1:14-24.
21. Ohuchi M, Asaoka N, Sakai T, Ohuchi R. Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect 2006; 8: 1287-93.
22. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 2006;70, 3:121-31.
23. Van RK. Cytokines in the pathogenesis of influenza. Vet Microbiol 2000;74, 1-2:109-16.
24. Guillot L, Le GR, Bloch S, Escriou N, Akira S, Chignard M, et al. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 2005;280, 7:5571-80.
25. Ludwig S, Pleschka S, Planz O, Wolff T. Ringing the alarm bells: signalling and apoptosis in influenza virus infected cells. Cell Microbiol 2006;8, 3:375-86.
26. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et al. Re-emergence of fatal human influenza A subtype H5N1 disease. Lancet 2004;363, 9409:617-9.
27. Asai Y, Hashimoto S, Kujime K, Gon Y, Mizumura K, Shimizu K, et al. Amantadine inhibits RANTES production by influenzavirus-infected human bronchial epithelial cells. Br J Pharmacol 2001,132, 4:918-24.
28. Seki M, Yanagihara K, Higashiyama Y, Fukuda Y, Kaneko Y, Ohno H, et al. Immunokinetics in severe pneumonia due to influenza virus and bacteria coinfection in mice. Eur Respir J 2004;24, 1:143-9.
29. Regoes RR, Bonhoeffer S. Emergence of drug-resistant influenza virus: population dynamical considerations. Science 2006;312, 5772:389-91.
30. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006;295, 8:891-4.
31. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364, 9436:759-65.
32. de J, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, et al. Oseltamivir resistance during treatment of influenza A H5N1 infection. N Engl J Med 2005;353, 25:2667-72.
33. Anonymous. Antiviral drugs in influenza: an adjunct to vaccination in some situations. Prescribe Int 2006;15:21-30.